Abstract
Somatostatin receptor expression, which was not a previously described marker for Hurthle cell cancer of the thyroid, was demonstrated by in vivo imaging with 111In-pentetreotide in three patients. This phenomenon not only adds another imaging technique to the nuclear medicine armamentarium for detecting recurrent and metastatic cancer in patients with Hurthle cell cancer but also opens up an alternative therapeutic avenue with somatostatin analogs or their radiolabeled compounds.
| Original language | English |
|---|---|
| Pages (from-to) | 243-245 |
| Number of pages | 3 |
| Journal | Journal of Nuclear Medicine |
| Volume | 39 |
| Issue number | 2 |
| State | Published - Feb 1 1998 |
Fingerprint
Keywords
- Hurthle cell cancer
- Indium-111- pentetreotide
- Somatostatin receptors
- Thyroid cancer
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
Cite this
Somatostatin receptor expression in Hurthle cell cancer of the thyroid. / Gulec, Seza A.; Serafini, Aldo N; Sridhar, Kasi S.; Peker, Kamil R.; Gupta, Anurag; Goodwin, W. Jarrard; Sfakianakis, George N; Moffat, Frederick L.
In: Journal of Nuclear Medicine, Vol. 39, No. 2, 01.02.1998, p. 243-245.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Somatostatin receptor expression in Hurthle cell cancer of the thyroid
AU - Gulec, Seza A.
AU - Serafini, Aldo N
AU - Sridhar, Kasi S.
AU - Peker, Kamil R.
AU - Gupta, Anurag
AU - Goodwin, W. Jarrard
AU - Sfakianakis, George N
AU - Moffat, Frederick L
PY - 1998/2/1
Y1 - 1998/2/1
N2 - Somatostatin receptor expression, which was not a previously described marker for Hurthle cell cancer of the thyroid, was demonstrated by in vivo imaging with 111In-pentetreotide in three patients. This phenomenon not only adds another imaging technique to the nuclear medicine armamentarium for detecting recurrent and metastatic cancer in patients with Hurthle cell cancer but also opens up an alternative therapeutic avenue with somatostatin analogs or their radiolabeled compounds.
AB - Somatostatin receptor expression, which was not a previously described marker for Hurthle cell cancer of the thyroid, was demonstrated by in vivo imaging with 111In-pentetreotide in three patients. This phenomenon not only adds another imaging technique to the nuclear medicine armamentarium for detecting recurrent and metastatic cancer in patients with Hurthle cell cancer but also opens up an alternative therapeutic avenue with somatostatin analogs or their radiolabeled compounds.
KW - Hurthle cell cancer
KW - Indium-111- pentetreotide
KW - Somatostatin receptors
KW - Thyroid cancer
UR - http://www.scopus.com/inward/record.url?scp=0031916461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031916461&partnerID=8YFLogxK
M3 - Article
C2 - 9476928
AN - SCOPUS:0031916461
VL - 39
SP - 243
EP - 245
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
SN - 0161-5505
IS - 2
ER -